2-(pyrazol-1-yl)cyclohexanone | 208576-44-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(pyrazol-1-yl)cyclohexanone
• 英文别名: 2-(1H-pyrazol-1-yl)cyclohexan-1-one；2-pyrazol-1-ylcyclohexan-1-one
• CAS: 208576-44-7
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: XOXHZVGTMVFYJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.57
• 重原子数：
  12.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  34.89
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-(pyrazol-1-yl)cyclohexanone 在 potassium phosphate 、 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 三氟化硼乙醚 作用下， 以 1,4-二氧六环 、 苯 为溶剂， 反应 18.5h， 生成
  参考文献：
  名称：

  JAK2 INHIBITOR COMPOUNDS

  摘要：

  Described herein are compounds that are JAK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditions associated with JAK2 activity.

  公开号：

  WO2024044486A1
• 作为产物：
  描述：

  环己酮 在 盐酸 、 L-脯氨酸 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 31.0h， 生成 2-(pyrazol-1-yl)cyclohexanone
  参考文献：
  名称：

  JAK2 INHIBITOR COMPOUNDS

  摘要：

  Described herein are compounds that are JAK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditions associated with JAK2 activity.

  公开号：

  WO2024044486A1

文献信息

• [EN] COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS<br/>[FR] COMPOSÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013027001A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6, X1, X2, X3, X4, A1 and L1, are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（1）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、m、n、p、q、Q1、Q2、Q3、Q4、Q5、Q6、X1、X2、X3、X4、A1和L1如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• Unexpected direction in the cyclization of α,α'-diaminated cyclopentanone with malonic dialdehyde tetramethyl acetal
  作者：A. A. Utkina、A. V. Kurkin、M. A. Yurovskaya

  DOI：10.1007/s10593-012-1072-5

  日期：2012.9

  New compounds were unexpectedly discovered in a detailed study of the cyclization of α-aminated carbocyclic ketones with malonic dialdehyde tetramethyl acetal, in addition to the formation of the corresponding pyrazoles. In the case of cyclopentanone these new products are 6,7-dihydro-2H-cyclo-penta[c]pyridazine-4-carbaldehyde and 3-hydroxy-2,2-di(1H-pyrazol-1-yl)cyclopentanone. For cyclo-hexanone

  除形成相应的吡唑外，在用丙二醛二醛四甲基乙缩醛对α-胺基碳环酮进行环化的详细研究中意外发现了新化合物。在环戊酮的情况下，这些新产品是6,7-二氢-2 H-环戊[ c ]哒嗪-4-甲醛和3-羟基-2,2-二（1 H-吡唑-1-基）环戊酮。对于环己酮，是环化成吡唑的中间体，即1-（2-氧代-环己基）-2-（3-氧代丙-1-烯-1-基）肼甲酸的叔丁酯，被隔离了。
• JAK2 INHIBITOR COMPOUNDS
  申请人：[en]AJAX THERAPEUTICS, INC.

  公开号：WO2024044486A1

  公开（公告）日：2024-02-29

  Described herein are compounds that are JAK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditions associated with JAK2 activity.